Peter Llewellyn-Davies
Peter is Chief Executive Officer of APEIRON Biologics, a biotech company focused on the discovery and development of treatments for respiratory diseases and novel cancer immunotherapies. APEIRON are currently investigating a therapeutic candidate for the treatment of severe COVID-19.
Latest articles
Non-nurses being hired as nurses in hospitals and mental health facilities, RCN warns
The RCN is warning against growing instances of people without registered nurse qualifications being employed for registered nursing roles and compromising patient safety. The RCN...
Pf talks to Simon Nicholson, MD of Organon
It is long overdue, but women’s health is finally having its moment in the spotlight and it feels like there could be a big...
High street pharmacies making their inventory visible on Google
Over 400 high street pharmacies will now be better equipped to drive online shoppers in-store, by making their inventory visible on Google in real-time. With...
Popular articles
Access Matters: The rise of the payer and implications for pharma
In a two-part series exclusive to Pharmafield, Neil Grubert and Mel Walker, Managing Director at Biopharma Futures, explore key trends in international market access....
New Normal, New Thinking: Life Post COVID-19
New thinking will be required to adapt to the new normal life post COVID-19. I hate to start this article on a negative note, but...
Pf talks to Simon Nicholson, MD of Organon
It is long overdue, but women’s health is finally having its moment in the spotlight and it feels like there could be a big...
High street pharmacies making their inventory visible on Google
Over 400 high street pharmacies will now be better equipped to drive online shoppers in-store, by making their inventory visible on Google in real-time. With...
PHE confirms coronavirus Delta variant is now dominant in the UK
The weekly coronavirus update released by Public Health England (PHE) has shown that cases of the Delta (VOC-21APR-02) variant in the UK have risen...